C

CSPC Pharmaceutical Group Ltd
HKEX:1093

Watchlist Manager
CSPC Pharmaceutical Group Ltd
HKEX:1093
Watchlist
Price: 9.8 HKD -0.1% Market Closed
Market Cap: 112.9B HKD

Relative Value

The Relative Value of one CSPC Pharmaceutical Group Ltd stock under the Base Case scenario is 7.34 HKD. Compared to the current market price of 9.8 HKD, CSPC Pharmaceutical Group Ltd is Overvalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
7.34 HKD
Overvaluation 25%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
6
vs Industry
55
Median 3Y
2.4
Median 5Y
2.8
Industry
2.7
Forward
3.5
vs History
3
vs Industry
38
Median 3Y
12.6
Median 5Y
14.4
Industry
21.6
Forward
20.1
vs History
28
vs Industry
33
Median 3Y
14.8
Median 5Y
13.9
Industry
16.9
vs History
17
vs Industry
21
Median 3Y
30.3
Median 5Y
28.1
Industry
22.9
vs History
38
vs Industry
49
Median 3Y
2.4
Median 5Y
2.8
Industry
2.3
vs History
6
vs Industry
64
Median 3Y
1.9
Median 5Y
2.4
Industry
3
Forward
3.2
vs History
4
vs Industry
72
Median 3Y
2.6
Median 5Y
3.2
Industry
5.6
vs History
3
vs Industry
43
Median 3Y
7.6
Median 5Y
9.5
Industry
13.4
Forward
12.1
vs History
3
vs Industry
45
Median 3Y
7.9
Median 5Y
10.1
Industry
16.7
Forward
14.5
vs History
17
vs Industry
39
Median 3Y
11.4
Median 5Y
11.7
Industry
16.1
vs History
6
vs Industry
26
Median 3Y
23.5
Median 5Y
21.5
Industry
18.9
vs History
50
vs Industry
51
Median 3Y
2.2
Median 5Y
2.7
Industry
2

Multiples Across Competitors

Competitors Multiples
CSPC Pharmaceutical Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
CSPC Pharmaceutical Group Ltd
HKEX:1093
112.9B HKD 3.9 24.9 17.4 17.4
US
Eli Lilly and Co
NYSE:LLY
984.9B USD 16.6 53.7 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
522.9B USD 5.7 20.8 17 22
CH
Roche Holding AG
SIX:ROG
276.4B CHF 4.5 29.3 12.5 14.5
UK
AstraZeneca PLC
LSE:AZN
219.6B GBP 5.1 31.5 109 159.6
CH
Novartis AG
SIX:NOVN
222.4B CHF 5 19.3 12.2 15.8
US
Merck & Co Inc
NYSE:MRK
271.9B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 10.9 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
CN
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Average P/E: 24.9
24.9
8%
3.1
US
Eli Lilly and Co
NYSE:LLY
53.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Average EV/EBITDA: 401.6
17.4
3%
5.8
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
CH
Novartis AG
SIX:NOVN
12.2
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Average EV/EBIT: 1 714
17.4
5%
3.5
US
Eli Lilly and Co
NYSE:LLY
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.8
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5